Elms Steve
Director at ADMA; Director, 10% owner at Loxo Oncology, Inc.; Director at MAP Pharmaceuticals, Inc.
- Sold, on record
- $55.5M
- Dollars the filings state
- Form 4 sales
- 5
- Latest Jun 16, 2025
- Form 144 notices
- 1
- Proposed sales
- Quarters with a sale
- 1 of the last 8
- 1 day with a sale in that time
- Companies
- 3
- Filed as an executive or holder
Companies
- ADMAADMA BIOLOGICS, INC.Director
- Loxo Oncology, Inc.Director, 10% owner
- MAP Pharmaceuticals, Inc.Director
Sales by reason
0
Routine
1
Plan not stated
2
No plan
2
Unusual
Form 4 sales per year, every sale on record.
Sales by company
- ADMA1.9M shares
- Loxo Oncology, Inc.500,000 shares
- MAP Pharmaceuticals, Inc.2,090 shares
Shares sold, every Form 4 sale on record.
Timeline
- Jun 16, 2025No plan
Sold 17.3% of their holdings
$8.8M425,621 shares at $20.74
- Jun 12, 2025Notice
Filed a notice to sell 425,621 shares
$9.3M425,621 shares
- Mar 19, 2024No plan
Sold 17.9% of their holdings
$2.8M461,716 shares at $6.07
- Mar 15, 2024Unusual
Sold 28.7% of their holdings
$6.3M1M shares at $6.11
- Nov 22, 2017Plan not stated
Sold 11.9% of their holdings
$37.5M500,000 shares at $75.00
- Mar 10, 2010Unusual
Sold 100% of their holdings
$34k2,090 shares at $16.15
6 of 6
Every transaction
| Traded | Filed | Stock | Role | What | Amount | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|---|---|
| Mar 6, 2026 | Mar 9, 2026 | ADMA | Director | Bought | 14,000 | $15.53 | $217k | 2M | SEC |
| Feb 9, 2026 | Feb 11, 2026 | ADMA | Director | AwardedStock Option (Right to Buy) | 17,730 | 17,730 | SEC | ||
| Feb 9, 2026 | Feb 11, 2026 | ADMA | Director | Awarded | 10,690 | 98,020 | SEC | ||
| Nov 17, 2025 | Nov 19, 2025 | MRKR | Director | AwardedStock Option (right to buy) | 221,741 | 137,330 | SEC | ||
| Jul 23, 2025 | Jul 24, 2025 | Elevation Oncology, Inc. | Director | Returned to the companyStock Option (Right to Buy) | 148,095 | 0 | SEC | ||
| Jun 16, 2025 | Jun 16, 2025 | ADMA | Director | Sold | 425,621 | $20.74 | $8.8M | 87,330 | SEC |
| Jun 13, 2025 | Jun 16, 2025 | ADMA | Director | Exercised or settledStock Option (Right to Buy) | 332,680 | 0 | SEC | ||
| Jun 13, 2025 | Jun 16, 2025 | ADMA | Director | Exercised options | 332,680 | $3.43 | $1.1M | 420,010 | SEC |
| Jun 5, 2025 | Jun 9, 2025 | Elevation Oncology, Inc. | Director | AwardedStock Option (Right to Buy) | 35,000 | 35,000 | SEC | ||
| Feb 19, 2025 | Feb 21, 2025 | ADMA | Director | AwardedStock Option (Right to Buy) | 16,279 | 16,279 | SEC | ||
| Feb 19, 2025 | Feb 21, 2025 | ADMA | Director | Awarded | 10,889 | 87,330 | SEC | ||
| Feb 12, 2025 | Feb 14, 2025 | MRKR | Director | AwardedStock Option (right to buy) | 30,000 | 30,000 | SEC | ||
| Dec 23, 2024 | Dec 26, 2024 | MRKR | Director | Bought | 11,085 | $3.20 | $35k | 325,370 | SEC |
| Nov 27, 2024 | Dec 2, 2024 | ADMA | Director | Exercised or settledStock Option (Right to Buy) | 9,000 | 0 | SEC | ||
| Nov 27, 2024 | Dec 2, 2024 | ADMA | Director | Exercised options | 9,000 | $10.80 | $97k | 2.1M | SEC |
| Jun 13, 2024 | Jun 17, 2024 | Elevation Oncology, Inc. | Director | AwardedStock Option (Right to Buy) | 35,000 | 35,000 | SEC | ||
| Mar 19, 2024 | Mar 19, 2024 | ADMA | Director | Sold | 461,716 | $6.07 | $2.8M | 2.1M | SEC |
| Mar 15, 2024 | Mar 15, 2024 | ADMA | Director | Sold | 1M | $6.11 | $6.3M | 2.6M | SEC |
| Feb 26, 2024 | Feb 28, 2024 | ADMA | Director | AwardedStock Option (right to buy) | 37,541 | 37,541 | SEC | ||
| Feb 26, 2024 | Feb 28, 2024 | ADMA | Director | Awarded | 24,040 | 76,441 | SEC | ||
| Jun 6, 2023 | Jun 8, 2023 | MRKR | Director | AwardedStock Option (right to buy) | 8,000 | 8,000 | SEC | ||
| Mar 6, 2023 | Mar 8, 2023 | ADMA | Director | AwardedEmployee Stock Option (right to buy) | 51,630 | 51,630 | SEC | ||
| Mar 6, 2023 | Mar 8, 2023 | ADMA | Director | Awarded | 25,815 | 52,401 | SEC | ||
| May 24, 2022 | May 26, 2022 | MRKR | Director | AwardedStock Option (Right to Buy) | 80,000 | 80,000 | SEC | ||
| Mar 7, 2022 | Mar 9, 2022 | ADMA | Director | AwardedEmployee Stock Option (right to buy) | 53,172 | 53,172 | SEC | ||
| Mar 7, 2022 | Mar 9, 2022 | ADMA | Director | Awarded | 26,586 | 26,586 | SEC | ||
| Jun 10, 2021 | Jun 14, 2021 | Zosano Pharma Corp | Director | AwardedStock Option (Right to Buy) | 30,000 | 30,000 | SEC | ||
| Jun 10, 2021 | Jun 14, 2021 | Zosano Pharma Corp | Director | Awarded | 15,000 | 22,500 | SEC | ||
| Jun 8, 2021 | Jun 10, 2021 | MRKR | Director | Awarded | 12,658 | 29,680 | SEC | ||
| Mar 16, 2021 | Mar 18, 2021 | MRKR | Director | Bought | 1.1M | $1.75 | $2M | 3.1M | SEC |
| Feb 25, 2021 | Mar 1, 2021 | ADMA | Director | AwardedStock Option (right to buy) | 55,000 | 55,000 | SEC | ||
| Jun 25, 2020 | Jun 29, 2020 | Zosano Pharma Corp | Director | Awarded | 7,500 | 7,500 | SEC | ||
| Jun 3, 2020 | Jun 5, 2020 | Zosano Pharma Corp | Director | AwardedStock Option (Right to Buy) | 15,000 | 15,000 | SEC | ||
| May 19, 2020 | Feb 12, 2021 | MRKR | Director | Awarded | 17,022 | 17,022 | SEC | ||
| Feb 28, 2020 | Mar 3, 2020 | ADMA | Director | AwardedEmployee Stock Option (right to buy) | 15,000 | 15,000 | SEC | ||
| Feb 28, 2020 | Mar 3, 2020 | ADMA | Director | Awarded | 7,500 | 7,500 | SEC | ||
| Aug 6, 2019 | Aug 8, 2019 | MRKR | Director | AwardedStock Option (right to buy) | 12,500 | 12,500 | SEC | ||
| Apr 11, 2019 | Apr 12, 2019 | Zosano Pharma Corp | 10% owner | Awarded | 428,571 | $3.50 | $1.5M | 2M | SEC |
| Mar 13, 2019 | Mar 15, 2019 | ADMA | Director | AwardedStock Option (right to buy) | 30,000 | 30,000 | SEC | ||
| Feb 15, 2019 | Feb 15, 2019 | Loxo Oncology, Inc. | Director, 10% owner | Tendered | 2M | $235.00 | $479M | 2M | SEC |
| Feb 15, 2019 | Feb 15, 2019 | Loxo Oncology, Inc. | Director, 10% owner | Returned to the companyEmployee Stock Option (Right to Buy) | 50,999 | $235.00 | $12M | 0 | SEC |
| Jan 2, 2019 | Jul 18, 2019 | Zosano Pharma Corp | Director, 10% owner | AwardedStock Option (Right to Buy) | 1,500 | 1,500 | SEC | ||
| Jun 22, 2018 | Jun 25, 2018 | ADMA | Director | AwardedStock Option (right to buy) | 17,500 | 17,500 | SEC | ||
| Jun 13, 2018 | Jun 14, 2018 | Loxo Oncology, Inc. | Director, 10% owner | AwardedDirector Stock Option (right to buy) | 8,750 | 8,750 | SEC | ||
| May 17, 2018 | May 21, 2018 | Zosano Pharma Corp | Director, 10% owner | AwardedStock Option (right to buy) | 25,000 | 25,000 | SEC | ||
| Nov 22, 2017 | Nov 27, 2017 | Loxo Oncology, Inc. | Director, 10% owner | Sold | 500,000 | $75.00 | $37.5M | 3.7M | SEC |
| Jun 22, 2017 | Jun 23, 2017 | Loxo Oncology, Inc. | Director, 10% owner | AwardedDirector Stock Option (right to buy) | 11,000 | 11,000 | SEC | ||
| Jun 6, 2017 | Jun 8, 2017 | ADMA | Director, 10% owner | AwardedStock Option (right to buy) | 53,837 | 53,837 | SEC | ||
| Feb 14, 2017 | Feb 16, 2017 | ADMA | Director, 10% owner | AwardedStock Option (right to buy) | 10,000 | 10,000 | SEC | ||
| Jun 10, 2016 | Jun 13, 2016 | Loxo Oncology, Inc. | Director, 10% owner | AwardedDirector Stock Option (right to buy) | 7,812 | 7,812 | SEC |
Page 1
Sales and notices (6)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Jun 16, 2025 | Jun 16, 2025 | ADMA | Director | Form 4 sale | 425,621 | $8.8M | 17.3% | No plan | SEC |
| Jun 12, 2025 | Jun 12, 2025 | ADMA | Director | Form 144 notice | 425,621 | $9.3M | Notice | SEC | |
| Mar 19, 2024 | Mar 19, 2024 | ADMA | Director | Form 4 sale | 461,716 | $2.8M | 17.9% | No plan | SEC |
| Mar 15, 2024 | Mar 15, 2024 | ADMA | Director | Form 4 sale | 1M | $6.3M | 28.7% | Unusual | SEC |
| Nov 22, 2017 | Nov 27, 2017 | Loxo Oncology, Inc. | Director, 10% owner | Form 4 sale | 500,000 | $37.5M | 11.9% | Plan not stated | SEC |
| Mar 10, 2010 | Mar 12, 2010 | MAP Pharmaceuticals, Inc. | Director | Form 4 sale | 2,090 | $34k | 100.0% | Unusual | SEC |